Editorial Dept. Voz de la Diaspora
The government of El Salvador has concluded an agreement with AstraZeneca to supply 2 million doses of your vaccine AZD1222 against Covid-19, the announcement was notified by the laboratory through a statement.
the vaccine has been developed in conjunction with the University of Oxford, and it is estimated that it will be available for the first semester of the year 2021.
Rafael Mendoza, President of AstraZeneca for the Central America and Caribbean region, express: "At AstraZeneca, we reaffirm our commitment to promote broad and equitable access to the AZD1222 candidate vaccine in Central America and the Caribbean., in case it is safe and effective”.
Mendoza added: "We are honored that the Government of El Salvador has chosen the AZD1222 candidate vaccine as part of its vaccination plan against COVID-19 and we will continue to collaborate to co-create solutions and respond to the multiple challenges of this pandemic.".
Clinical trials are currently continuing in the UK, U.S, Brazil, South Africa, Japan, Kenya, Russia and several Latin American countries, with projected studies.
AstraZeneca, is a global scientific pharmaceutical company specializing in the discovery, prescription drug development and marketing, especially for the treatment of diseases in the areas of: Oncology, Renal and Metabolic, Respiratory and immunology and Cardiovascular.